{
}
State Street Corp has increased its stake in CRISPR Therapeutics to nearly 3 million shares, valued at $140.6 million. CEO Samarth Kulkarni and General Counsel James R. Kasinger recently sold shares, reducing their holdings. Analysts maintain a "Hold" rating on the stock, with a consensus price target of $78.38.
CRISPR Therapeutics experienced a 1.86% decrease in insider ownership following recent stock sales totaling over $2.7 million. Institutional investors hold 69.20% of the company, with Bank of America lowering its price target to $85, indicating a potential upside of 100.61%. The stock currently has a "Hold" rating among analysts, with a consensus target price of $78.38.
CRISPR Therapeutics has a consensus rating of "Hold" with a price target of $77.93, as analysts remain divided with two sell, eight hold, and nine buy ratings. The stock opened at $40.48, reflecting a market cap of $3.46 billion and a P/E ratio of -14.30. In its latest earnings report, the company beat EPS estimates but fell short on revenue, posting a loss of $1.01 per share against expectations of $1.42.
CRISPR Therapeutics insiders have sold 50,382 shares worth $2.74 million in the last 90 days, with insiders owning 4.10% of the company. Institutional investors hold 69.20% of the stock, while analysts maintain a "Hold" rating, with a consensus target price of $77.93. The company's recent earnings report showed a loss of $1.01 per share, exceeding expectations, but revenue fell short at $0.60 million.
Larson Financial Group LLC increased its stake in CRISPR Therapeutics by 95.5% in Q2, now holding 565 shares valued at $31,000. Other institutional investors also made significant investments, with ownership among them at 69.20%. CRISPR Therapeutics, focused on gene-editing for serious diseases, recently hit a 52-week low of $40.61, with analysts giving it a consensus "Hold" rating and an average price target of $77.93.
CRISPR Therapeutics AG (NASDAQ:CRSP) experienced a 6.4% decline in short interest in November, totaling 18,150,000 shares. Analysts have mixed ratings, with a consensus "Hold" and a target price of $77.93, while CEO Samarth Kulkarni sold 30,000 shares, reducing his stake by 13.24%. The company reported a quarterly EPS of ($1.01), surpassing estimates, but revenue fell short at $0.60 million.
CRISPR Therapeutics' CEO sold shares at an average price of $46.28, totaling $198,680.04, reducing their ownership by 1.86%. General Counsel James R. Kasinger also sold shares, resulting in a 1.71% decrease in their holdings. Insiders have sold 50,382 shares valued at $2,744,179 in the last three months, with 4.10% of the stock owned by insiders. The company reported a quarterly loss of $1.01 EPS, exceeding estimates, while analysts maintain a "Hold" rating with a consensus target price of $77.93.
Larson Financial Group LLC and GPS Wealth Strategies Group LLC significantly increased their stakes in CRISPR Therapeutics during the second quarter, with institutional investors now owning 69.20% of the company. The stock recently hit a 52-week low of $43.23, and analysts have mixed ratings, with a consensus "Hold" and an average target price of $77.93. In its latest earnings report, CRISPR posted a loss of $1.01 per share, beating estimates but falling short on revenue expectations.
CRISPR Therapeutics (NASDAQ: CRSP) has seen a reduction in Q2 2025 earnings estimates to ($1.48) per share, with a full-year consensus of ($5.17) per share. Analysts have mixed ratings, with two sell, eight hold, and nine buy ratings, while the stock is currently trading at $47.78, down 1.8%. Institutional investors hold 69.20% of the company, reflecting ongoing interest despite recent insider selling.
William Blair forecasts CRISPR Therapeutics will report FY2024 earnings of ($4.66) per share, slightly better than the consensus estimate of ($5.17). The company recently posted Q3 earnings of ($1.01) per share, exceeding expectations, but reported revenues significantly below estimates. Analysts maintain a "Hold" rating on the stock, with a mixed outlook reflected in various price targets.
James Kasinger
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
state street increases stake in crispr therapeutics amid insider stock sales
13:18 09.01.2025
insider sales and institutional investments impact crisper therapeutics stock performance
19:33 07.01.2025
crispr therapeutics stock ratings and performance analysis update
09:55 24.12.2024
insider sales and hedge fund activity at crispr therapeutics raise eyebrows
15:09 20.12.2024
crispr therapeutics shares hit new low amid mixed analyst ratings
12:18 19.12.2024
crispr therapeutics experiences drop in short interest and mixed analyst ratings
04:20 17.12.2024
insider trades and stock performance update for crisper therapeutics
09:52 15.12.2024
institutional investors increase stakes in crisper therapeutics amid stock fluctuations
20:55 14.12.2024
analysts lower earnings estimates for crispr therapeutics amid mixed ratings
13:37 12.12.2024
insider trading activity and earnings forecast for crispr therapeutics
13:21 11.12.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Supply Chain Management
Global Trade Developments
Industry Mergers & Acquisitions
Government Economic Policies
Cryptocurrency Trends
Financial Scams and Security
Workplace Trends
CEO Changes
Venture Capital Investments
Finance Mergers & Acquisitions
Fintech Startups
Consumer Protection Regulations
Retail and Consumer Goods
Market Analysis and Predictions
Funding Rounds & Investments
Emerging Startups
Global Trade Policies
Countries:
Companies:
Apple Inc.
Google Inc.
NVIDIA Corporation
Delhivery Limited
Ecom Express Ltd.
Alphabet Inc.
OpenAI ERC USD
Ciscom Corp.
ERICSSON - CLASS B
Physicswallah Ltd.
Snap Inc.
Tiktok USD
Semiconductor Manufacturing International Corporation
Hua Hong Semiconductor Ltd.
Spotify Technology S.A.
Dropbox, Inc.
Vimeo, Inc.
Adobe Inc.
Airbnb, Inc.
SpaceXCoin USD
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Vietnamese Đồng
Russian Ruble
South Korean Won
Pakistani Rupee
Algerian Dinar
Australian Dollar
Thai Baht
New Taiwan Dollar
People: